Investor Presentation
Deal
Deal value—
Deal vs businessCapacity expansion from 21.7k to 33.7k MTPA (~55% volume growth) plus CCS and API diversification
Execution period2.0 yr
Fundamental gradeC
AI projections
Revenue uplift (yr1 / steady)36.0% / 72.0%
EPS uplift150.0%
Upside base / bull / bear45.0% / 90.0% / -25.0%
Horizon12-24 months
Realized market record
Entry — next-day open (14 Aug 2026)₹26.39
Latest close (16 Oct 2026)₹27.52
Return since+4.3%
α vs Smallcap 250+8.3%
α vs own sectorshown once held 90+ days — Pharmaceuticals - Indian - Bulk Drugs & Formln median is -6.0% over 52 matured picks
Positives
- Operational turnaround in Q1 FY27 with PAT returning to ₹8.2 Cr post major fire losses in FY26
- Capacity expansion underway from 21.7k to 33.7k MTPA at Dahej SEZ providing long-term volume visibility
- Strong FY27 management guidance targeting ₹650-675 Cr revenue with 18-20% EBITDA margin
- Strategic move into higher-margin Croscarmellose Sodium (CCS) and active API business via Trimax acquisition
Risks
- 100% dependency on imported wood pulp exposing gross margins to foreign exchange and supply price shocks
- Concentrated operational footprint and low promoter holding at 36.69%
- Restoration delay risk for the Pashamylaram manufacturing unit
Governance flags
- Major fire incident causing ₹118 Cr exceptional loss in FY26 highlighting operational control vulnerability
- Promoter holding near low threshold at 36.69%
Full AI brief
Sigachi Industries (SIGACHI) - Investment Thesis & Catalyst Analysis
1. Executive Summary & Quality Gate
- Verdict: POSSIBLE
- Multibagger Score: 52/100
- Fundamental Grade: C (Impacted by FY26 exceptional fire loss, but operational metrics rebounding)
- Quality Gate: Failed trailing test due to low ROCE (7.0%) caused by Pashamylaram unit fire disruption. However, operational recovery is clearly visible in Q1 FY27.
2. Ramp-Aware Financial & Catalyst Math
- Base TTM Revenue: ₹478 Cr
- FY27 Management Guidance: ₹650 - 675 Cr (implies ~36% Year-1 growth over TTM).
- Steady-State Potential: Full utilization of 33,700 MTPA capacity (Dahej SEZ +12,000 MTPA) plus CCS and API contributions can take revenue to ₹825-850 Cr (+72% uplift over TTM).
- Margin Profile: Q1 FY27 EBITDA margin reached 13.6%, with full-year target set at 18-20%. At steady-state ₹825 Cr revenue and 18% OPM, EBITDA equals ~₹148 Cr.
- EPS Acceleration: Post-depreciation and interest, steady-state PAT reaches ~₹80-85 Cr (EPS ₹2.50 - 2.70), representing a 150%+ uplift over normalized prior levels.
3. Industry Dynamics & Execution Risks
- Capital Intensity: MEDIUM. Excipient (MCC) and API manufacturing requires moderate capex with continuous maintenance.
- Industry CAGR: ~8-10% structural growth in pharma excipients.
- Key Vulnerabilities: 100% imported wood pulp exposes margins to commodity cost spikes. Furthermore, promoter holding stands low at 36.69%.
4. Calibrated Valuation Scenarios (12-24 Month Horizon)
- Bull Case (+90%, Target ₹52): Successful capacity ramp-up to 33.7k MTPA, EBITDA margins achieve top-end guidance (20%), PAT reaches ₹90 Cr, valued at 20x P/E.
- Base Case (+45%, Target ₹39.5): Revenue hits ₹660 Cr in FY27 and ₹780 Cr in FY28 with 17% OPM, PAT reaches ₹65 Cr, valued at 18x P/E.
- Bear Case (-25%, Target ₹20.4): Input cost inflation in wood pulp suppresses margins to 12%, delayed Dahej ramp-up, PAT stagnates at ₹35 Cr, stock de-rates to 15x P/E.
5. Rationale & Conclusion
Sigachi presents a classic turnaround-to-growth story following severe fire disruption in FY26. Q1 FY27 results prove core operational viability is restored. While promoter stake is thin and raw material risk is high, the massive capacity addition provides solid structural visibility over a 12-24 month horizon.
Analysis as of 2026-08-13 (price ₹27.24) ·
AI research, not investment advice.
FollowTelegram
